scholarly journals Evidence Update: Antipsychotics for Children with Hyperactivity or Disruptive Disorders

2018 ◽  
Author(s):  
Keyword(s):  
Children And Adolescents ◽  
Antipsychotic Treatment ◽  
Disruptive Disorders ◽  
New Evidence

New evidence can help clinicians, caretakers, and others weigh the benefits and harms of antipsychotic treatment for children and adolescents.

scholarly journals Comorbidity in Juvenile Obsessive—Compulsive Disorder: A Report from India

2000 ◽  
Vol 45 (3) ◽  
pp. 274-278 ◽  
Author(s):  
YC Janardhan Reddy ◽  
P Srinivas Reddy ◽  
S Srinath ◽  
S Khanna ◽  
SP Sheshadri ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Children And Adolescents ◽  
Obsessive Compulsive Disorder ◽  
Structured Interview ◽  
Child And Adolescent Psychiatry ◽  
Tic Disorders ◽  
Obsessive Compulsive ◽  
Interview Schedule ◽  
Compulsive Disorder ◽  
Disruptive Disorders

Objective: Using minimal exclusion criteria, to assess systematically the psychiatric comorbidity in children and adolescents with obsessive–compulsive disorder (OCD) and compare the findings with those of previous studies. Method: Fifty-four children and adolescents who satisfied DSM-III-R criteria for OCD were assessed using a structured interview schedule, the Children's version of the Yale-Brown Obsessive Compulsive Scale (CY-BOCS), and the questionnaire for tic disorders. All 54 subjects were recruited from the Child and Adolescent Psychiatry (CAP) services of the National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, South India. Diagnoses were determined consensually after a review of all the available data. Results: Comorbidity was found in 69% of the sample: 22% were diagnosed with disruptive disorders; 20% met criteria for mood disorders; 19% had anxiety disorders; and 17% had tic disorders. Only 1 subject had bipolar disorder, and none had psychosis. The rates for individual diagnoses—in particular, the rates for disruptive disorders, bipolar disorder, and psychosis—were considerably lower than those reported in previous studies. Conclusions: Patterns of comorbidity in this study differed from those previously reported. Novel patterns of comorbidity with disruptive disorders, bipolar disorder, and psychosis reported in a few recent studies were not replicated in this study. These differences are probably due to different ascertainment methods. Comorbidity needs to be assessed in large epidemiological samples before definite associations can be made between certain comorbid disorders and juvenile OCD.

QTc Changes after 6 Months of Second-Generation Antipsychotic Treatment in Children and Adolescents

2008 ◽  
Vol 18 (4) ◽  
pp. 381-383 ◽  
Author(s):  
María J. de Castro ◽  
David Fraguas ◽  
Paula Laita ◽  
Dolores Moreno ◽  
Mara Parellada ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Second Generation ◽  
Antipsychotic Treatment ◽  
Second Generation Antipsychotic

Use of atypical antipsychotics in early onset schizophrenia

2011 ◽  
Vol 26 (S2) ◽  
pp. 324-324
Author(s):  
M. Marin Mayor ◽  
N. Martinez Martin ◽  
E. Verdura Vizcaino ◽  
R.A. Codesal Julian
Keyword(s):  
Side Effects ◽  
Children And Adolescents ◽  
Early Onset ◽  
Atypical Antipsychotics ◽  
Metabolic Effects ◽  
Psychotic Symptoms ◽  
Antipsychotic Treatment ◽  
Childhood And Adolescence ◽  
Early Onset Schizophrenia ◽  
Children And Adolescent

IntroductionChildhood or Early Onset Schizophrenia (EOS), defined as the onset of psychotic symptoms before the thirteenth birthday, represents a rare, clinically severe variant, associated with significant chronic functional impairment and poor response to antipsychotic treatment. Despite of that, in clinical practice, atypical agents have become the treatment of choice in patients with EOS.AimsTo review the different pharmacological strategies, in which an atypical antipsychotic was used in the management of EOS in childhood and adolescence.MethodsWe conducted a literature search of articles related to the use of atypical antipsychotics in children and adolescents with EOS in the last 20 years from the Medline database.ResultsSeveral atypical antipsychotics, such as Risperidone, Olanzapine, Quetiapine, Aripiprazol and Clozapine were consistently found to reduce the severity of psychotic symptoms in EOS when compared to placebo. Although Clozapine has demonstrated to be more efficacious than other atypical and typical antipsychotics, it remains the medication of last resort due to its profile of side effects. Finally, in general, children and adolescent have a higher risk of extrapyramidal symptoms, akathisia, prolactin elevation, sedation and metabolic effects of atypical antipsychotics than adults.ConclusionsAntipsychotics are the mainstay of treatment of EOS. Randomized controlled trials suggest a trend to superior efficacy for atypical antipsychotics over classic antipsychotic. Children and adolescents trend to be more sensible to antipsychotic side effects. Clinicians should be aware of this problem and be careful when monitoring this type of treatment.

Reproductive Adverse Events Associated with Antipsychotic Treatment in Children and Adolescents

2008 ◽  
Vol 21 (2) ◽  
pp. 82
Author(s):  
Jeanette M. Jerrell ◽  
Janice L. Bacon ◽  
Judith T. Burgis ◽  
Seema Menon
Keyword(s):  
Adverse Events ◽  
Children And Adolescents ◽  
Antipsychotic Treatment

scholarly journals Antipsychotic treatment for children and adolescents with schizophrenia spectrum disorders: protocol for a network meta-analysis of randomised trials

BMJ Open ◽  
2014 ◽  
Vol 4 (10) ◽  
pp. e005708 ◽  
Author(s):  
A K Pagsberg ◽  
S Tarp ◽  
D Glintborg ◽  
A D Stenstrøm ◽  
A Fink-Jensen ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Empirical Bayes ◽  
Meta Analysis ◽  
Control Group ◽  
Antipsychotic Treatment ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Central Registry ◽  
Meta Analyses ◽  
Indirect Comparisons

IntroductionAntipsychotic treatment in early-onset schizophrenia (EOS) lacks a rich evidence base, and efforts to rank different drugs concerning their efficacy have not proven any particular drug superior. In contrast to the literature regarding adult-onset schizophrenia (AOS), comparative effectiveness studies in children and adolescents are limited in number and size, and only a few meta-analyses based on conventional methodologies have been conducted.Methods and analysesWe will conduct a network meta-analysis of all randomised controlled trials (RCTs) that evaluate antipsychotic therapies for EOS to determine which compounds are efficacious, and to determine the relative efficacy and safety of these treatments when compared in a network meta-analysis.Unlike a contrast-based (standard) meta-analysis approach, an arm-based network meta-analysis enables statistical inference from combining both direct and indirect comparisons within an empirical Bayes framework. We will acquire eligible studies through a systematic search of MEDLINE, the Cochrane Central Registry of Controlled Trials, Clinicaltrials.gov and Centre for Reviews and Dissemination databases. Eligible studies should randomly allocate children and adolescents presenting with schizophrenia or a related non-affective psychotic condition to an intervention group or to a control group. Two reviewers will—independently and in duplicate—screen titles and abstracts, complete full text reviews to determine eligibility, and subsequently perform data abstraction and assess risk of bias of eligible trials. We will conduct meta-analyses to establish the effect of all reported therapies on patient-relevant efficacy and safety outcomes when possible.Ethics and disseminationNo formal ethical procedures regarding informed consent are required as no primary data collection is undertaken. The review will help facilitate evidence-based management, identify key areas for future research, and provide a framework for conducting large systematic reviews combining direct and indirect comparisons. The study will be disseminated by peer-reviewed publication and conference presentation.Trial registration numberPROSPERO CRD42013006676.

Secondary effects of antipsychotic treatment in naïve or quasi-naïve children and adolescents: Design of a follow-up protocol and baseline results

2012 ◽  
Vol 5 (4) ◽  
pp. 217-228 ◽  
Author(s):  
Jessica Merchán-Naranjo ◽  
Cecilia Tapia ◽  
Concha Bailón ◽  
Carmen Moreno ◽  
Inmaculada Baeza ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Antipsychotic Treatment ◽  
Secondary Effects
Sign in / Sign up

Export Citation Format

Share Document